21.18
21.18 (0%)
As of Apr 29, 2025
Anaptysbio, Inc [ANAB]
Source:
Company Overview
Anaptysbio, Inc is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Our pipeline includes our lead program, rosnilimab, a depleter and agonist targeting PD-1 T cells, in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (“RA”) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (“UC”).
| Country | United States |
| Headquarters | san diego, california |
| Phone Number | (858) 362-6295 |
| Industry | manufacturing |
| CEO | Daniel Faga |
| Website | www.anaptysbio.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $91.3 |
| Operating Profit | $-114.9 |
| Net Income | $-145.2 |
| Net Cash | $87.1 |
Profit Ratios
| Gross Margin | $91.3 |
| Operating Margin | -125.9 |
| Profit as % of Revenues | -62.9% |
| Profit as % of Assets | -31% |
| Profit as % of Stockholder Equity | -204.9% |
Management Effectiveness
| Return on Equity | -204.9% |
| Return on Assets | -30% |
| Turnover Ratio | 19.5% |
| EBITA | $-114.9 |
Balance Sheet and Cash Flow Measures
| Total Assets | $483.8 |
| Total Liabilities | $413 |
| Operating Cash Flow | $-135.3 |
| Investing Cash Flow | $95.4 |
| Financing Cash Flow | $127.1 |
